FDA requests Tavneos market withdrawal due to ADVOCATE trial assessment concerns; Amgen maintains the drug's benefit-risk profile remains positive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results